Mizuho lowered the firm’s price target on Biogen (BIIB) to $207 from $251 and keeps an Outperform rating on the shares. The analyst updated models in the biotechnology group following the Q3 reports. Biogen’s Q3 contained no major surprises, but Mizuho cut the price target on a slow Leqembi launch, the analyst tells investors in a research note. The firm continues to see the Biogen story as a longer term positive, largely on how and when the Leqembi launch could accelerate.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BIIB:
- QQQ ETF Update, 11/21/2024
- VOO ETF Update, 11/20/2024
- SPY ETF Update, 11/19/2024
- UCB, Biogen present results from PHOENYCS GO study
- Spirit enters into bankruptcy proceedings, CVS names new directors: Morning Buzz
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
